In a crucial development for hospitals and COVID-19 patients, the World Health Organisation (WHO) has rejected antiviral drug Remdesivir as a COVID treatment. After conducting several trials, the WHO found that the drug did not improve survival rates for patients nor did it help them recover.
Gilead, the manufacturer of Remdesivir said it is disappointed with WHOs recommendation against the drug. The company has reiterated that the drug does help in faster recovery and is being used across 50 countries to treat the deadly virus.
As many Indian hospitals continue to rely on Remdesivir as the treatment for COVID-19, CNBC-TV18’s Archana Shukla gives details on how this will impact the treatment in India.